Ervexia Occupational Health Ervexia vs Clearview Franchising

Clearview Franchising is the stronger opportunity right now, and it’s not close. The dimension that wins is TAM — total addressable market. With 12 total units and 8 franchised, Clearview gives you a base of live operating locations to sell into immediately, plus a franchisor relationship that can unlock the other 4 as they convert. Ervexia’s 3 total units and single franchised location make it a rounding error by comparison. Even if you close 100% of Ervexia, you’ve sold 3 seats. Clearview at 50% penetration still puts 6 deals on the board.

The tradeoff is budget vs. timing. Ervexia’s $892k AUV and 8% royalty suggest healthier unit economics and more cash to spend on software, and the CURRENT FDD filing signals an active, compliant franchisor ready to engage now. Clearview’s investment range is lower, its royalty is a punishing 20%, and the DUE filing status means you’re walking into a franchisor that may be distracted or disorganized. That’s a real risk to deal velocity. But in B2B franchise sales, volume of storefronts almost always beats per-unit wallet size when you’re hunting pipeline, and Clearview simply has more doors to knock on.

Verdict: Clearview wins on raw unit count and franchised base despite weaker unit economics and filing risk — volume cures most sins in franchise software sales.